Distinguised New Specialists Enhance Urologic Cancer Treatment and Research at OHSU

04/15/05    Portland, Ore.

Sokoloff and Daneshmand will expand treatment options for patients with kidney, prostate and other urologic cancers

Mitchell Sokoloff, M.D., has joined Oregon Health & Science University as an associate professor in the Division of Urology and chief of the Section of Urologic Oncology in the OHSU School of Medicine, and as a member of the OHSU Cancer Institute.

Siamak Daneshmand, M.D., has joined OHSU as an assistant professor in the Division of Urology in the OHSU School of Medicine, and as a member of the OHSU Cancer Institute.

"We are pleased to welcome Sokoloff and Daneshmand who join another fellowship-trained urologic oncologist, Mark Garzotto, at OHSU and the OHSU Cancer Institute," said John Barry, M.D., chairman, Division of Urology, and professor of surgery in the OHSU School of Medicine.

Mark Garzotto, M.D., is the director of urologic oncology at the Portland Veterans Affairs Medical Center, associate professor of surgery, OHSU School of Medicine, and a member of the OHSU Cancer Institute.

"This trio will enhance the treatment and research programs already in place, further develop the urologic oncology educational programs, and usher in a new era of cooperation with our nationally known urologic medical oncologists and radiation oncologists," said Barry.

"The recruitment of Sokoloff and Daneshmand significantly adds to the scope of our multidisciplinary urologic oncology program," said Christopher Ryan, M.D., assistant professor of medicine (hematology/medical oncology) and member of the OHSU Cancer Institute."I am particularly excited about our clinical trial collaborations and the new options we are offering to patients with kidney, prostate, bladder, and testis cancer. This provides a unique resource for cancer patients in the Pacific Northwest."

For the previous five years, Sokoloff was at the University of Chicago where he created an innovative translational and clinical research program. He was instrumental in expanding the use of pioneering surgical procedures, including nerve sparing and robotic surgery for prostate cancer, and nephron-sparing and minimally invasive laparoscopic surgery for kidney cancer. Sokoloff is involved with several national cancer intergroups on large multi-institution clinical trials.

"My goals at OHSU are to expand the use of minimally invasive and laparoscopic technologies in cancer therapies and to use innovative drug therapies in combination with surgery to target locally advanced, metastatic and high-risk tumors," said Sokoloff. He designed and currently directs a Phase II clinical study evaluating anti-angiogenesis drugs in combination with prostatectomy for men with high-risk prostate cancer, work that resulted from research performed in his research.

Sokoloff received his medical degree from Stanford University. His internship and residency were at the University of California at Los Angeles, and he completed a prestigious American Foundation of Urologic Diseases Fellowship at the University of Virginia.

"Sokoloff's and Daneshmand's commitment to innovative surgical care and research will enhance the services we offer to men with prostate cancer. We are both proud and fortunate to have him join our prostate cancer team," said Tomasz Beer, M.D., director of the Prostate Cancer Program in the OHSU Cancer Institute and associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.
A specialist in urologic oncology, Daneshmand received his medical degree from the University of California at Davis. He completed his residency at the University of Southern California (USC) and then completed a two-year fellowship in urologic oncology at the Norris Comprehensive Cancer Center at USC, where many innovative methods of bladder reconstruction were pioneered for bladder cancer patients.

Daneshmand has extensive experience in the surgical care of patients with advanced genitourinary cancers and kidney cancers, as well as with nerve-sparing techniques in prostate, bladder and testicular cancers. Clinically, Daneshmand emphasizes a multidisciplinary, patient-centered clinical practice and is a strong patient and family advocate.

"All patients have options that are unique to their circumstances, whether it's surgery, chemotherapy, radiation or a combination of the three treatments. Family support is very important when making these major treatment decisions," said Daneshmand.

Daneshmand's research includes evaluating the diagnostic and prognostic value of certain proteins in prostate cancer and identifying the factors that affect late-stage recurrence of bladder cancers.